Everyday Pain Relievers Linked to Hearing Loss in Women

Women who used ibuprofen (Advil, Motrin) or acetaminophen (Tylenol) for six year or more were more likely to suffer hearing loss than those who used the pain relievers for a year or less, said researchers from Brigham and Women’s Hospital in Boston.

They found no significant association between long-term aspirin use and hearing loss.

“Although the magnitude of higher risk of hearing loss with analgesic use was modest, given how commonly these medications are used, even a small increase in risk could have important health implications,” study senior author Dr. Gary Curhan said in a hospital news release.

For the study, Curhan’s team analyzed data from more than 54,000 women, ages 48 to 73, in the Nurses’ Health Study.

Longer use of ibuprofen or acetaminophen was associated with potentially higher risk of impaired hearing.

The researchers noted that most of the women in the study were older and white. They said larger studies that include other groups of people are needed to learn more about the possible link between pain relievers and hearing loss.

The research team previously found that higher use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDS) was associated with increased risk of hearing loss in men and younger women.

“Hearing loss is extremely common in the United States and can have a profound impact on quality of life,” Curhan said. “Finding modifiable risk factors could help us identify ways to lower risk before hearing loss begins and slow progression in those with hearing loss.”

Acetaminophen During Pregnancy May Up Risk of ADHD in Kids

Pregnant women who take acetaminophen – best known as Tylenol – might raise the risk that their child will develop behavioral problems such as attention-deficit/hyperactivity disorder (ADHD), a new study suggests.

Acetaminophen is generally considered safe in pregnancy – so safe, in fact, that at least two-thirds of women turn to it while expecting, according to the American Academy of Family Physicians.

But when pregnant women in Britain used the pain reliever, it appeared to increase the risk of behavior problems cropping up in their children by the time they turned 7, said lead researcher Evie Stergiakouli, a lecturer in genetic epidemiology at the University of Bristol.

Still, the study couldn’t prove cause-and-effect, and Stergiakouli believes that women should still take the drug if needed.

In the study, taking acetaminophen between 18 and 32 weeks in pregnancy was associated with a 42% increased risk of behavior problems in children and a 31% increased risk of hyperactivity, the researchers found.

No similar association cropped up in mothers who used acetaminophen after delivery, nor did it occur if the father used the over-the-counter drug, the findings showed.

“Only acetaminophen used during pregnancy has the potential to cause behavioral problems in the offspring,” Stergiakouli said.

These findings jibe with two other large-scale studies that have suggested acetaminophen may have an adverse effect on a baby’s brain during pregnancy, said Dr. Andrew Adesman. He is chief of developmental and behavioral pediatrics at Cohen Children’s Medical Center in New Hyde Park, N.Y.

Study Casts Doubt on Acetaminophen for Low Back Pain, Arthritis

Acetaminophen – best know as Tylenol in the United States – does not appear to help ease lower back pain and offers little relief for the most common form of arthritis, according to a new report.

The review of data from 13 studies could challenge existing recommendations on pain relief, experts say.

“These results support the reconsideration of recommendations to use [acetaminophen] for patients’ with these conditions," concluded a team led by Gustavo Machado of The George Institute for Global Health at the University of Sydney in Australia.

The researchers analyzed 10 studies that examined the use of acetaminophen to treat osteoarthritis of the hip or knee, and three studies that assessed the use of the painkiller for lower back pain.

Osteoarthritis – the most common form of arthritis – and back pain are among the leading causes of disability worldwide, the researchers said. Current clinical guidelines recommend acetaminophen as the first-line drug treatment for both conditions.

However, doubts about the effectiveness of the drug in treating the conditions, and concerns about the safety of the recommended full dose (up to 4,000 milligrams a day), have made those guidelines controversial, Machado’s team said.
Looking at the pooled data, the investigators found that for people with lower back pain, acetaminophen was ineffective in either reducing patient disability or enhancing quality of life.

Tylenol ‘does not ease low-back pain’

Low back pain is the main cause of disability worldwide and acetaminophen (brand name Tylenol) is currently the first port of call in terms of reducing pain and speeding recovery.

However, a large randomized trial published in The Lancer investigates the efficacy of acetaminophen for acute low back pain and finds it performs no better than a placebo.

The researchers, led by Dr. Christopher Williams from the George Institute for Global Health at the University of Sydney, Australia, say their findings bring into question the “universal endorsement” of acetaminophen as the main painkiller for low back pain.

After conducting a systematic review of previous studies assessing the effectiveness of acetaminophen for low back pain, the team found no evidence to support its use. “All seven of the included trials had substantial methodological flaws, and only one trial included more than 25 participants per group,” they write. Additionally, they say no trial has compared acetaminophen with a placebo or compared dosing.

Their study randomly assigned 1,652 participants, of an average age of 45 years, with low back pain to receive regular doses of acetaminophen (3,990 mg per day) for up to 4 weeks; a second group was given acetaminophen as needed, and the third group a placebo. Results showed that between the treatment groups, there were no differences in the number of days to recovery; the median time to recovery was 17 days for the regular dose group, 17 days for the as needed group and 16 days for the placebo group.